Nadeem A. Vellore
Research Subjects
Nadeem A. Vellore has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Alexandria van Scoyk
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
20 shared publications - Ami B. Patel
Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA
20 shared publications Anca Franzini
20 shared publications- Angelo D'Alessandro
University of Colorado Anschutz Medical Campus
20 shared publications Anna V. Senina
20 shared publications- Anthony D. Pomicter
Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT, USA
20 shared publications
Latest Publications
- Open Access
- 25 April 2023
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 120 (18)
Identification of small-molecule protein–protein interaction inhibitors for NKG2D
NKG2D (natural-killer group 2, member D) is a homodimeric transmembrane receptor that plays an important role in NK, γδ + , and CD8 + T cell-mediated immune responses to environmental stressors such as viral or bacterial infections and oxidative stress. However, aberrant NKG2D signaling has also been associated with chronic inflammatory and autoimmune diseases, and as such NKG2D is thought to be an attractive target for immune intervention. Here, we describe a comprehensive small-molecule hit identification strategy and two distinct series of protein–protein interaction inhibitors of NKG2D. Although the hits are chemically distinct, they share a unique allosteric mechanism of disrupting ligand binding by accessing a cryptic pocket and causing the two monomers of the NKG2D dimer to open apart and twist relative to one another. Leveraging a suite of biochemical and cell-based assays coupled with structure-based drug design, we established tractable structure–activity relationships with one of the chemical series and successfully improved both the potency and physicochemical properties. Together, we demonstrate that it is possible, albeit challenging, to disrupt the interaction between NKG2D and multiple protein ligands with a single molecule through allosteric modulation of the NKG2D receptor dimer/ligand interface.
- 25 April 2023
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 120 (18)
Open AccessIdentification of small-molecule protein–protein interaction inhibitors for NKG2D
NKG2D (natural-killer group 2, member D) is a homodimeric transmembrane receptor that plays an important role in NK, γδ + , and CD8 + T cell-mediated immune responses to environmental stressors such as viral or bacterial infections and oxidative stress. However, aberrant NKG2D signaling has also been associated with chronic inflammatory and autoimmune diseases, and as such NKG2D is thought to be an attractive target for immune intervention. Here, we describe a comprehensive small-molecule hit identification strategy and two distinct series of protein–protein interaction inhibitors of NKG2D. Although the hits are chemically distinct, they share a unique allosteric mechanism of disrupting ligand binding by accessing a cryptic pocket and causing the two monomers of the NKG2D dimer to open apart and twist relative to one another. Leveraging a suite of biochemical and cell-based assays coupled with structure-based drug design, we established tractable structure–activity relationships with one of the chemical series and successfully improved both the potency and physicochemical properties. Together, we demonstrate that it is possible, albeit challenging, to disrupt the interaction between NKG2D and multiple protein ligands with a single molecule through allosteric modulation of the NKG2D receptor dimer/ligand interface.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from SIRT5 Is a Druggable Metabolic Vulnerability in Acute Myeloid Leukemia
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from SIRT5 Is a Druggable Metabolic Vulnerability in Acute Myeloid Leukemia
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from SIRT5 Is a Druggable Metabolic Vulnerability in Acute Myeloid Leukemia
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from SIRT5 Is a Druggable Metabolic Vulnerability in Acute Myeloid Leukemia
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from SIRT5 Is a Druggable Metabolic Vulnerability in Acute Myeloid Leukemia
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from SIRT5 Is a Druggable Metabolic Vulnerability in Acute Myeloid Leukemia
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from SIRT5 Is a Druggable Metabolic Vulnerability in Acute Myeloid Leukemia
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from SIRT5 Is a Druggable Metabolic Vulnerability in Acute Myeloid Leukemia
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from SIRT5 Is a Druggable Metabolic Vulnerability in Acute Myeloid Leukemia
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from SIRT5 Is a Druggable Metabolic Vulnerability in Acute Myeloid Leukemia
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from SIRT5 Is a Druggable Metabolic Vulnerability in Acute Myeloid Leukemia
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from SIRT5 Is a Druggable Metabolic Vulnerability in Acute Myeloid Leukemia
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from SIRT5 Is a Druggable Metabolic Vulnerability in Acute Myeloid Leukemia
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from SIRT5 Is a Druggable Metabolic Vulnerability in Acute Myeloid Leukemia
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 7 from SIRT5 Is a Druggable Metabolic Vulnerability in Acute Myeloid Leukemia
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 7 from SIRT5 Is a Druggable Metabolic Vulnerability in Acute Myeloid Leukemia
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 8 from SIRT5 Is a Druggable Metabolic Vulnerability in Acute Myeloid Leukemia
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 8 from SIRT5 Is a Druggable Metabolic Vulnerability in Acute Myeloid Leukemia